Compare JUBILANT LIFE SCIENCES with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES ELDER PHARMA JUBILANT LIFE SCIENCES/
ELDER PHARMA
 
P/E (TTM) x 13.6 -0.2 - View Chart
P/BV x 1.6 0.1 1,577.5% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   ELDER PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
ELDER PHARMA
Jun-14
JUBILANT LIFE SCIENCES/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs898380 236.3%   
Low Rs618188 328.5%   
Sales per share (Unadj.) Rs572.0491.2 116.5%  
Earnings per share (Unadj.) Rs36.2-3.2 -1,138.6%  
Cash flow per share (Unadj.) Rs59.514.4 413.0%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs301.9376.5 80.2%  
Shares outstanding (eoy) m159.2820.54 775.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.6 229.1%   
Avg P/E ratio x20.9-89.3 -23.4%  
P/CF ratio (eoy) x12.719.7 64.6%  
Price / Book Value ratio x2.50.8 332.7%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m120,6945,833 2,069.0%   
No. of employees `0002.4NA-   
Total wages/salary Rs m19,2602,179 883.9%   
Avg. sales/employee Rs Th38,120.6NM-  
Avg. wages/employee Rs Th8,058.4NM-  
Avg. net profit/employee Rs Th2,414.3NM-  
INCOME DATA
Net Sales Rs m91,10810,089 903.0%  
Other income Rs m357257 139.3%   
Total revenues Rs m91,46610,346 884.1%   
Gross profit Rs m17,390-792 -2,196.0%  
Depreciation Rs m3,709361 1,026.6%   
Interest Rs m2,1982,756 79.7%   
Profit before tax Rs m11,840-3,653 -324.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8023,713 -75.5%   
Tax Rs m3,268125 2,611.3%   
Profit after tax Rs m5,770-65 -8,829.5%  
Gross profit margin %19.1-7.8 -243.2%  
Effective tax rate %27.6-3.4 -805.6%   
Net profit margin %6.3-0.6 -977.8%  
BALANCE SHEET DATA
Current assets Rs m45,8489,240 496.2%   
Current liabilities Rs m20,8979,998 209.0%   
Net working cap to sales %27.4-7.5 -364.7%  
Current ratio x2.20.9 237.4%  
Inventory Days Days5746 122.6%  
Debtors Days Days5160 85.0%  
Net fixed assets Rs m65,49810,124 647.0%   
Share capital Rs m159206 77.4%   
"Free" reserves Rs m47,9305,582 858.6%   
Net worth Rs m48,0897,734 621.8%   
Long term debt Rs m42,4294,889 867.8%   
Total assets Rs m114,68522,882 501.2%  
Interest coverage x6.4-0.3 -1,963.4%   
Debt to equity ratio x0.90.6 139.6%  
Sales to assets ratio x0.80.4 180.2%   
Return on assets %6.911.8 59.1%  
Return on equity %12.0-0.8 -1,419.9%  
Return on capital %12.422.3 55.6%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m12,422307 4,051.5%   
Fx outflow Rs m17,227125 13,748.6%   
Net fx Rs m-4,805181 -2,650.3%   
CASH FLOW
From Operations Rs m11,21511,754 95.4%  
From Investments Rs m-10,118-561 1,805.2%  
From Financial Activity Rs m6,574-6,762 -97.2%  
Net Cashflow Rs m7,6124,432 171.8%  

Share Holding

Indian Promoters % 45.6 39.6 115.2%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 7.5 116.0%  
FIIs % 21.2 16.8 126.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 36.1 58.4%  
Shareholders   23,815 16,479 144.5%  
Pledged promoter(s) holding % 15.9 77.6 20.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Gains 300 Points; Hero MotoCorp & Maruti Suzuki Top Gainers(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Signs of easing trade tension between the US and China provided some respite to investors globally.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Oct 15, 2019 01:53 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - STRIDES PHARMA SCIENCE COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS